Synthetic biology deal: $600M upfront

Bristol Myers Squibb and Hengrui Pharma said on May 12 they signed strategic collaboration and licensing agreements covering 13 early-stage programs in oncology, hematology and immunology, in a package that could be worth as much as $15.2 billion. The companies announced the deal from Princeton, New Jersey, and Shanghai, describing it as a global partnership built around assets from both pipelines and jointly discovered programs. The headline number starts with $600 million upfront from Bristol Myers Squibb. The companies also disclosed $350 million in near-term commitments and up to $14.25 billion in development, regulatory and sales milestone payments, taking the stated total potential value to $15.2 billion. Industry outlets including STAT and Fierce Biotech reported the structure on May 12 as one of the largest recent cross-border biopharma partnering deals. (investors.bms.com) The 13-program package includes four oncology and hematology assets from Hengrui, four immunology assets from Bristol Myers Squibb and five programs to be jointly discovered and developed, according to the companies’ statement. Bristol Myers Squibb said it will get exclusive worldwide rights to Hengrui-originated assets outside mainland China, Hong Kong and Macau, while Hengrui will receive exclusive rights to the Bristol Myers-originated assets in those markets, with Bristol Myers retaining rights elsewhere. (investors.bms.com) Hengrui will be fully responsible for early clinical development under the collaboration, Bristol Myers Squibb said, with the stated aim of accelerating proof-of-concept work. Hengrui also has an option to co-develop select assets and may conduct certain commercialization activities globally with Bristol Myers. (investors.bms.com) Robert Plenge, Bristol Myers Squibb’s executive vice president and chief research officer, said in the release that the agreement reflects the company’s effort to advance innovative science while keeping “a disciplined approach to portfolio management.” He said the partners aimed to “accelerate early clinical learning” by combining capabilities across geographies. (investors.bms.com) Hengrui described the transaction as part of its broader partnering strategy. The company’s English-language site posted the announcement on May 12 alongside its recent quarterly and annual updates, underscoring the agreement’s place in its current investor communications. The structure also fits a broader pattern in biopharma licensing. J.P. Morgan said in an April 2026 report that announced licensing value reached $82.7 billion in the first quarter, with upfront cash accounting for 6% of total deal value and contingent payments carrying most of the headline figures. (investors.bms.com) Third-quarter 2026 is the next concrete milestone. (hengrui.com) Bristol Myers Squibb and Hengrui said the agreements are expected to close in that quarter, subject to customary closing conditions and regulatory approvals, after which the companies would begin advancing the 13-program portfolio under the terms laid out in the May 12 announcement. (investors.bms.com) (jpmorgan.com)